Skip to content

Clinical Evaluation of Daily Disposable Etafilcon A Cosmetic Contact Lenses

Clinical Evaluation of Daily Disposable Etafilcon A Cosmetic Contact Lenses

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04529109
Enrollment
58
Registered
2020-08-27
Start date
2020-08-13
Completion date
2020-09-15
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Visual Acuity

Brief summary

This will be a randomized, double-masked, bilateral, cross-over, 2 treatment by 2 period dispensing study. There will be 4 visits. There will be a 2 to 5 day washout period between treatments.

Interventions

DEVICEetafilcon A investigational cosmetic lens 1

TEST

DEVICEetafilcon A investigational cosmetic lens 2

CONTROL

Sponsors

Johnson & Johnson Vision Care, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 29 Years
Healthy volunteers
Yes

Inclusion criteria

-Potential subjects must satisfy all of the following criteria to be enrolled in the study: 1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form 2. Females between 18 and 29 (inclusive) years of age at the time of screening 3. Appear able and willing to adhere to the instructions set forth in this clinical protocol (i.e. willing to wear only the study lenses and not use habitual lenses during the dispensing periods) 4. Be a current soft contact lens wearer in both eyes with a minimum of 6 hours/day and 5 days/week over the last month by self-report 5. Be a current wearer of cosmetic/circle lenses in the last 6 months, by self-report. 6. The subject must be willing to be photographed and/or video-taped 7. The subject's vertex corrected spherical equivalent distance refraction must be in the range of -1.00 D to -6.00 D (inclusive) in each eye 8. The subject's refractive cylinder must be less than or equal to 0.75 D (inclusive) in each eye 9. Have spherical best corrected visual acuity of 20/25 or better in each eye.

Exclusion criteria

1. Currently pregnant or lactating 2. Any systemic disease (eg, Sjögren's Syndrome), allergies, infectious disease (eg, hepatitis, tuberculosis), contagious immunosuppressive diseases (eg, HIV), autoimmune disease (eg, rheumatoid arthritis), or other diseases, by self-report, which are known to interfere with contact lens wear and/or participation in the study (at the investigators discretion) 3. Use of systemic medications (eg, chronic steroid use) that are known to interfere with contact lens wear (at the investigators discretion) 4. Any previous or planned (during the study) ocular surgery (eg, radial keratotomy, PRK, LASIK, etc.). 5. Any previous history or signs of a contact lens-related corneal inflammatory event (eg, past peripheral ulcer or round peripheral scar), or any other ocular abnormality that would contraindicate contact lens wear (at the investigators discretion). 6. Participation in any contact lens or lens care product clinical trial within seven (7) days prior to study enrollment 7. Employee or family members of clinical site (eg, Investigator, Coordinator, Technician) 8. Any ocular allergies, infections or other ocular abnormalities that are known to interfere with contact lens wear and/or participation in the study. This may include, but not be limited to entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, or corneal distortion (at the investigators discretion) 9. Clinically significant (Grade 3 or 4 on FDA scale) tarsal abnormalities, bulbar injection, corneal edema, corneal vascularization, corneal staining, or any other abnormalities of the cornea which would contraindicate contact lens wear.

Design outcomes

Primary

MeasureTime frameDescription
Proportion of Eyes With Distance Monocular Visual Acuity (logMAR) Lower Than 0.176 logMAR5- Minutes Post-Lens FittingVisual acuity on logMAR (Logarithm of Minimal Angle of Resolution) scale was evaluated at distance (4 meters) under high luminance high contrast lighting condition using ETDRS (Early Treatment Diabetic Retinopathy Study) charts. Letter-by-letter results calculated the visual performance score for each chart read. logMAR scores closer to zero, or below zero, indicate a better visual acuity. However, the data was dichotomized as Y=1 if logMAR visual acuity was less than 0.176 logMAR; and Y=0 otherwise. A value of 0.176 logMAR ≅20/30 Snellen Visual Acuity. The proportion of eyes with visual acuity lower than 0.176 logMAR was reported.

Countries

Hong Kong, United States

Participant flow

Recruitment details

A total of 58 subjects were enrolled into this study. Of those enrolled, 56 were dispensed at least 1 study lens, while 2 subjects failed to meet all eligibility criteria. Of those dispensed, 55 subjects completed the study while 1 subject was discontinued.

Withdrawals & dropouts

PeriodReasonFG000FG001
Period 1Unsatisfactory Lens Fitting due to Test Article01

Baseline characteristics

CharacteristicTotal
Age, Continuous23.1 years
STANDARD_DEVIATION 2.42
Race/Ethnicity, Customized
American Indian or Alaska Native
1 participants
Race/Ethnicity, Customized
Asian
41 participants
Race/Ethnicity, Customized
Black or African American
4 participants
Race/Ethnicity, Customized
Other
1 participants
Race/Ethnicity, Customized
White
9 participants
Region of Enrollment
China
39 participants
Region of Enrollment
United States
17 participants
Sex: Female, Male
Female
56 Participants
Sex: Female, Male
Male
0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 550 / 56
other
Total, other adverse events
0 / 550 / 56
serious
Total, serious adverse events
0 / 550 / 56

Outcome results

Primary

Proportion of Eyes With Distance Monocular Visual Acuity (logMAR) Lower Than 0.176 logMAR

Visual acuity on logMAR (Logarithm of Minimal Angle of Resolution) scale was evaluated at distance (4 meters) under high luminance high contrast lighting condition using ETDRS (Early Treatment Diabetic Retinopathy Study) charts. Letter-by-letter results calculated the visual performance score for each chart read. logMAR scores closer to zero, or below zero, indicate a better visual acuity. However, the data was dichotomized as Y=1 if logMAR visual acuity was less than 0.176 logMAR; and Y=0 otherwise. A value of 0.176 logMAR ≅20/30 Snellen Visual Acuity. The proportion of eyes with visual acuity lower than 0.176 logMAR was reported.

Time frame: 5- Minutes Post-Lens Fitting

Population: All subjects who had successfully completed all visits and did not substantially deviate from the protocol.

ArmMeasureValue (NUMBER)
Test (Etafilcon A With Cosmetic Pattern)Proportion of Eyes With Distance Monocular Visual Acuity (logMAR) Lower Than 0.176 logMAR0.9998 proportion of eyes
Control (Etafilcon A With Cosmetic Pattern)Proportion of Eyes With Distance Monocular Visual Acuity (logMAR) Lower Than 0.176 logMAR0.9998 proportion of eyes
95% CI: [0.999, 1]Bayesian Binary model

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026